参考文献/References:
[1]GRITSCH S, BATCHELOR TT, GONZALEZ CASTRO LN. Diag-nostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system [J]. Cancer, 2022, 128(1): 47-58.
[2]LOUIS DN, PERRY A, WESSELING P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary [J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[3]VERDUGO E, PUERTO I, MEDINA M. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment [J]. Cancer Commun (Lond), 2022, 42(11): 1083-1111.
[4]HUANG M, KE Y, SUN X, et al. Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1α [J]. Oncol Rep, 2014, 32(5): 1973-1980.
[5]DANESHIMEHR F, BARABADI Z, ABDOLAHI S, et al. Angiogenesis and its targeting in glioblastoma with focus on clinical approaches [J]. Cell J, 2022, 24(10): 555.
[6]PELLERINO A, BRUNO F, SOFFIETTI R, et al. Antiangiogenic therapy for malignant brain tumors: does it still matter [J]. Curr Oncol Rep, 2023, 25(7): 777-785.
[7]LIU M, RUAN X, LIU X, et al. The mechanism of BUD13 m6A methylation mediated MBNL1-phosphorylation by CDK12 regulating the vasculogenic mimicry in glioblastoma cells [J]. Cell Death Dis, 2022, 13(12): 1017.
[8]MANIOTIS AJ, FOLBERG R, HESS A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry [J]. Am J Pathol, 1999, 155(3): 739-752.
[9]XIANG T, LIN YX, MA W, et al. Vasculogenic mimicry formation in EBV-associated epithelial malignancies [J]. Nat Commun, 2018, 9 (1): 5009.
[10]YUE WY, CHEN ZP. Does vasculogenic mimicry exist in astrocytoma [J]. J Histochem Cytochem, 2005, 3(8): 997-1002.
[11]RICCI-VITIANI L, PALLINI R, BIFFONI M, et al. Tumour vascu-larization via endothelial differentiation of glioblastoma stem-like cells [J]. Nature, 2010, 468(7325): 824-828.
[12]BISEROVA K, JAKOVLEVS A, ULJANOVS R, et al. Cancer stem cells: significance in origin, pathogenesis and treatment of glioblas-toma [J]. Cells, 2021, 10(3): 621.
[13]LIU TJ, SUN BC, ZHAO XL, et al. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer [J]. Oncogene, 2013, 32(5): 544-553.
[14]XIAO Y, YU D. Tumor microenvironment as a therapeutic target in cancer [J]. Pharmacol Ther, 2021, 221: 107753.
[15]FANG C, CEN D, WANG Y, et al. ZnS@ZIF-8 core-shell nanopar-ticles incorporated with ICG and TPZ to enable H2S-amplified synergistic therapy [J]. Theranostics, 2020, 10(17): 7671-7682.
[16]WEI X, CHEN Y, JIANG X, et al. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments [J]. Mol Cancer, 2021, 20(1): 1-18.
[17]JIA J, CHU L, ZENG X, et al. GOLPH3 promotes vascular mimicry via the epithelial mesenchymal transition in glioblastoma cells [J]. Turk Neurosurg, 2023, 33(5): 722-730.
[18]LIU Q, QIAO L, LIANG N, et al. The relationship between vasculo-genic mimicry and epithelial-mesenchymal transitions [J]. J Cell Mol Med, 2016, 20(9): 1761-1769.
[19]DING XC, WANG LL, ZHANG XD, et al. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia [J]. J Hematol Oncol, 2021, 14(1): 1-5.
[20]FERNNDEZ-BARRAL A, ORGAZ JL, GOMEZ V, et al. Hypoxia negatively regulates antimetastatic PEDF in melanoma cells by a hypoxia inducible factor-independent, autophagy dependent mechanism [J]. PLoS One, 2012, 7(3): e32989.
[21]LE JONCOUR V, GUICHET PO, DEMBL KP, et al. Targeting the urotensin II/UT G protein-coupled receptor to counteract angioge-nesis and mesenchymal hypoxia/necrosis in glioblastoma [J]. Front Cell Dev Biol, 2021, 9: 652544.
[22]TUNCKALE T, CALISKAN T, POTOGLU B, et al. Investigation of serum E-Cadherin, VEGF121, survivin, tenascin C and tetraspanin 8 levels in patients with glioblastoma [J]. Bratisl Lek Listy, 2023, 124(4): 304-308.
相似文献/References:
[1]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(02):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述 高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强 杨吉安 邵灵敏 吴庭枫 刘宝辉 陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(02):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇 冯 军 黄俊红 白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(02):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕 孟凡华 刘魏然 魏春晓 林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(02):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元 王汉东 樊友武 贾 玥 吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(02):69.
[7]郑锐哲 姜秀峰 陈二涛 孙兆良 冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(02):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安 陆 南 贺亚龙 章 翔 刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴 蛟 易 勇 赵卓琳 周良学 周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]